To enhance the antimicrobial spectrum of the quinolones against anaerobic organisms and gram-positive bacteria, we investigated in two studies the parenteral combinations of ciprofloxacin (200 mg) and ofloxacin (200 mg) with metronidazole (500 mg) or clindamycin (600 mg) and the oral combinations of enoxacin (400 mg) and fleroxacin (400 mg) with metronidazole (400 mg), clindamycin (300 mg), or ornidazole (500 mg) (only with fleroxacin). The pharmacokinetics and serum bactericidal activities (SBAs) against 5 aerobic and 2 anaerobic species (total, 58 strains) were determined in two groups of 10 healthy volunteers by using a randomized crossover study design. The additions of metronidazole, clindamycin, and ornidazole did not affect the pharmacokinetics of the quinolones. The combination of clindamycin with ciprofloxacin, ofloxacin, and, to a lesser extent, fleroxacin resulted in an increase of the SBA against gram-positive strains (mean peak titers): Staphylococcus aureus, ciprofloxacin alone, 1:5.5; ciprofloxacin-clindamycin, 1:19.9; ofloxacin alone, 1:3.6; ofloxacin-clindamycin, 1:17.5; fleroxacin alone, 1:4.3; fleroxacin-clindamycin, 1:8.1; Streptococcus pneumoniae (fleroxacin and enoxacin were not tested), ciprofloxacin alone, 1:2.0; ciprofloxacin-clindamycin, 1:53; ofloxacin alone, 1:2.6; and ofloxacin-clindamycin, 1:49.2. The high SBA of quinolones against gram-negative bacteria was not affected by the combinations; however, relatively low activities against Pseudomonas aeruginosa were detected. In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2
The development of the fluoroquinolones has resulted in antimicrobial agents with enhanced gram-negative activity, including moderate activity against Pseudomonas aeruginosa (46). However, despite the broad antibacterial spectrum of quinolones, most anaerobic pathogens and several gram-positive strains such as staphylococci and streptococci are only moderately susceptible (1, 41) . Thus, in some clinical situations, a combination with other antibacterial agents is needed to expand the antibacterial spectrum. Examples are miscellaneous infections with aerobic and anaerobic bacteria (such as aspiration pneumonia or intraabdominal infections), for which initial therapy has to be empiric, or the empiric therapy of febrile neutropenic patients (12) . Metronidazole, ornidazole, and clindamycin have an antibacterial spectrum that includes most anaerobes; clindamycin is active against gram-positive pathogens as well (9, 25) .
Ciprofloxacin appears to be microbiologically the most active quinolone and is available for both oral and parenteral administration (1, 19, 46) .
When first introduced, ofloxacin could only be administered orally, but recently a parenteral form has been developed with favorable pharmacokinetic properties, including high serum concentrations and a long terminal half-life, resulting in a higher area under the concentration-time curve (AUC) than for ciprofloxacin (11, 15, 27) .
Fleroxacin is a new trifluorinated quinolone characterized * Corresponding author.
by a large antibacterial spectrum similar to those of ofloxacin, pefloxacin, enoxacin, and norfloxacin and by improved pharmacokinetic properties, i.e., a long terminal half-life and a high volume of distribution. Thus, an oral once-a-day treatment seems to be possible (6, 13, 31, 33, 42) . Enoxacin is available as an oral and parenteral drug characterized by a high bioavailability, a good tissue penetration after oral administration, and an antibacterial spectrum similar to that of fleroxacin (6) . In contrast to fleroxacin, twice-daily administration is necessary because of the shorter half-life (7) .
Generally, in combination therapy with two antibiotics, microbiological as well as pharmacokinetic interactions are possible. The purpose of this study was to investigate the pharmacokinetic properties and possible interactions as well as the antibacterial efficacy of combinations of quinolones with clindamycin, metronidazole, and ornidazole in volunteers. The determination of serum bactericidal activity (SBA) usually gives better information of antibacterial activity of specific antibiotics than in vitro methods do, especially when these data are conflicting (35) .
MATERIALS AND METHODS
Volunteers. Two groups of 10 healthy volunteers (5 males and 5 females) with no known allergies to the antimicrobial agents participated in each of both studies. Informed written consent was obtained from all volunteers. None of the females were pregnant, and none of the volunteers took any other antimicrobial agent or drug during the 4 weeks preceding the studies or during the studies. Subjects had normal biochemical and hematological profiles. In study I, the intravenous combinations of ciprofloxacin and ofloxacin with metronidazole or clindamycin were investigated. In study II, the oral combinations of enoxacin with metronidazole or clindamycin and the oral combinations of fleroxacin with metronidazole, clindamycin, and ornidazole were studied.
In study I, the mean age of the volunteers was 27.7 (range, 21 to 35) years, the mean body weight was 67.6 ± 10.1 (range, 56 to 81) kg, and the mean body surface area was 1.80 + 0.10 (range, 1.60 to 2.03) M2. The prestudy creatinine clearance was 106 ± 11 (range, 93.0 to 128.0) ml/min.
In study II, the mean age was 26 (range, 20 to 32) years, the mean body weight was 68 ± 12 (range, 49 to 85) kg, the mean body surface area was 1.83 ± 0.20 (range, 1.48 to 2.11) mi2, and the prestudy creatinine clearance was 115 ± 14 (range, 95 to 132) ml/min. Dosage. In a crossover randomized study design, the volunteers received the quinolone alone or in combination with the other agents with a time interval of at least 1 week between each administration.
In study I, the volunteers received ciprofloxacin (200 mg intravenously [i.v.]) and ofloxacin (200 mg i.v.) alone as well as each in combination with metronidazole (500 mg i.v.) or clindamycin (600 mg i.v.). Each agent was infused constantly over 30 min with a perfusor pump (Braun AG, Melsungen, Federal Republic of Germany) via a peripheral venous access. Ofloxacin was given as ofloxacin hydrochloride (HOE 280, batch 16) in 50 ml of a 0.9% NaCl solution.
In study II, the subjects received enoxacin (400 mg orally) alone and in combination with metronidazole (400 mg orally) or clindamycin (300 mg orally) and they also received fleroxacin (400 mg orally) alone and in combination with metronidazole (400 mg orally), clindamycin (300 mg orally), or ornidazole (500 mg orally). All drugs were given after a 12-h fasting period. Each tablet was swallowed with 100 ml of tap water. The fasting state was maintained for 1 additional hour and followed by a fluid intake of 1,000 ml through hours 1 to 6 and by breakfast after hour 2.
Sampling. Blood samples were obtained before and immediately after infusion (0 h) and 0.25, 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 8.0, 12, and 24 h following the end of infusion. Urine was collected before administration and at intervals from 0 to 6, 6 to 12, 12 to 24, and 24 to 48 h following administration. In the fleroxacin study, additional blood samples were obtained after 30, 36 , and 48 h, and the urine was collected for an additional interval (48 to 7A h) after administration. Serum and urine samples were frozen at -70°C and assayed during the following 3 months.
Measurement. Concentrations of ciprofloxacin, ofloxacin, and metronidazole were measured by high-performance liquid chromatography by previously described methods (5, 27, 30) . Enoxacin, the metabolite oxoenoxacin, fleroxacin, and omidazole were determined by high-performance liquid chromatography as well as by using modified methods according to previously described procedures for ciprofloxacin and ofloxacin (5, 19, 27) .
For enoxacin, the limits of detection were 0.025 mg/liter in serum and 0.1 mg/liter in urine; for the metabolite oxoenoxacin, the limit of detection was 2 mg/liter in urine. The day-to-day precisions of the assay were 7.3% at 1.22 mg/liter and 9.2% at 0.37 mg/liter in serum for enoxacin and 5.0% at 186 mg/liter for oxoenoxacin in urine. For metronidazole, the detection limit was 0.3 mg/liter in serum. Day-to-day precision (coefficient of variation) was 2.1% at 8.6 mg/liter (in serum). For fleroxacin, the limits of detection were 0.05 mg/liter in serum and 1.4 mg/liter in urine. The precisions of the assay were 2.5% at 2.3 mg/liter (in serum) and 2.6% at 225 mg/liter (in urine). For ornidazole, the limits of detection were 0.2 mg/liter in serum and 0.1 mg/liter in urine. The precisions of the assay were 1.3% at 3.8 mg/liter (in serum) and 0.7% at 10.1 mg/liter (in urine). Concentrations of clindamycin in serum were determined by a gas-chromatographic method involving organic extraction, liquid-liquid partitioning, derivatization with heptafluorobutyric anhydride, and capillary gas chromatography by using electron capture detection. The limit of detection was 0.01 mg/liter in serum. The precisions of the assay were 1.7% at 0.5 mg/liter and 19.4% at 0.1 mg/liter (unpublished method of Analytical Bio-Chemistry Laboratories, Inc., Upjohn Company, 1988).
Serum bactericidal activity and MIC determination. SBA was determined by using the method of Reller and Stratton (35) as previously described (3). All samples were serially diluted from 1:2 to 1:256.
In study I, the following test pathogens were tested against 1-h (peak) and 6-h (trough) sera of all volunteers: Staphylococcus aureus (10 strains), Streptococcus pneumoniae (10 strains), Escherichia coli (10 strains), Klebsiella pneumoniae (10 strains), Pseudomonas aeruginosa (10 strains), Bacteroides fragilis (6 strains), and Bacteroides thetaiotaomicron (2 strains).
In study II, the following test pathogens were tested against 2-h (peak) and 8-h (trough) sera of all volunteers: S. aureus (10 strains), E. coli (10 strains), K. pneumoniae (10 strains), P. aeruginosa (10 strains), B. fragilis (6 strains), and B. thetaiotaomicron (2 strains). A modification of the usual times for the determination of the SBA was chosen because of the expected highest concentrations of the antibiotics after oral application.
All aerobic strains were freshly isolated from clinical material by the Department of Microbiology (Klinikum Steglitz). The analysis of the anaerobic strains was performed by using basically the same method as described above with some modifications at Bayer Research Laboratories, Wuppertal-Elberfeld, Federal Republic of Germany. Instead of Mueller-Hinton broth, Schaedler broth was used. The whole procedure was performed under strictly anaerobic conditions, including addition of the bacterial suspension, incubation, and subculture Schaedler agar supplemented with 5% sheep blood.
For statistical analysis, the Wilcoxon test for paired differences was used. The level of significance was 0.05. The MICs of the antimicrobial agents for the aerobic strains were determined by a microdilution method as described previously (3). The MICs for the anaerobic strains were also determined at Bayer Research Laboratories according to the guidelines of the National Committee for Clinical Laboratory Standards and by using antibiotic concentrations from 32 to 0.015 mg/liter. In addition, the influence of supplementation with 50% inactivated human serum was studied.
The ranges of MICs and MBCs for the bacteroides strains were as follows (in mg/liter): clindamycin, <0.015 to 0. 5 The analysis of the substances were based on open two-and three-compartment models. To decide on the number of compartments, the Schwarz criterion was used. The pharmacokinetic parameters were calculated with the aid of these hybrid constants (A, B, and C and as, 1, and -y) (2, 14, 22 ). An iterative least-squares method was used to fit the constants to the experimental data of the serum concentration-time curve after normalization of concentrations in serum to a mean body weight of 70.0 kg (23) . The model constants were estimated by using a weighting scheme with WTi = Cj-' (WTi, weight; Ci, ith measured drug concentration) (32) . The duration of infusion was assessed by the method of Loo and Riegelman (28) . The mathematical calculations of the constants and the pharmacokinetic parameters were performed by standard methods as previously described (14, 19, 22, 26) . The Wilcoxon test for paired differences was used to decide on the differences in the pharmacokinetic parameters. The level of significance was 0.05.
In study II, the analysis was based on open one-and two-compartment models. For the pharmacokinetic calculations, a one-compartment model for extravascular application was used. The decision on the number of compartments, the pharmacokinetic calculations, and the statistical calculations were performed as described above (study I). .o -w00 increasing the mean value also. Since all volunteers including this particular volunteer had a normal renal function and since both measurement of the concentrations in serum and the pharmacokinetic calculations proved to be correct in all cases, we did not eliminate those volunteers from the calculation. The other pharmacokinetic parameters listed in Table 1 showed no significant differences (P > 0.05). SBAs after 1 and 6 h are shown in Table 2 . The combinations of ciprofloxacin and ofloxacin with clindamycin resulted in distinctly higher (P < 0.05) bactericidal activities against gram-positive strains, particularly S. aureus and S. pneumoniae. The high bactericidal activity against gram-negative pathogens was not influenced when the quinolones were given in combination with metronidazole or clindamycin; especially, there were no antagonistic effects. However, the activities against P. aeruginosa were relatively low. Also, the SBAs against anaerobic pathogens were generally low. Therefore, no benefit of the combination could be demonstrated on anaerobic bacteria. Serum inhibitory activities showed no great differences. Study II. Table 3 . No significant differences (P < 0.05) were found between single and combined application except a significant difference between the elimination half-life (P < 0.05) of enoxacin for the enoxacin-metronidazole combination and that for enoxacin in a single application.
RESULTS
SBAs after 2 and 8 h are listed in Table 4 . The combination of fleroxacin with clindamycin showed a slight increase of SBA against S. aureus (peak mean titers): fleroxacin alone, 1:4.3; and fleroxacin plus clindamycin, 1:8.1. However, clindamycin together with enoxacin did not increase the SBA against S. aureus. The high bactericidal activity against gram-negative strains was not influenced when fleroxacin was given in combination with metronidazole, cindamycin, or omidazole; in particular, no antagonistic effects were detected. However, a decrease of SBA against E. coli and K. pneumoniae could be detected when enoxacin was given with metronidazole (not statistically significant). As shown in study I, the activities both against P. aeruginosa and against anaerobic pathogens were relatively low. Therefore, the combination with metronidazole or clindamycin did not result in a significant increase of SBAs against anaerobic pathogens. Serum inhibitory activities did not differ to a large extent. 44), who investigated the combination of ciprofloxacin with clindamycin, metronidazole, cefotaxime, cefoxitin, and mezlocillin, synergy was noted with ciprofloxacin and cefotaxime for 16% of all tested isolates (including 44% of the B. fragilis group isolates) and with ciprofloxacin and clindamycin for 9% of all isolates (including 37% of Peptostreptococcus isolates), whereas antagonism occurred only rarely. The data reported by Krasemann showed synergy for the combinations of ciprofloxacin with metronidazole or clindamycin when members of the family Enterobacteriaceae, peptostreptococci, and clostridia were tested, whereas the combination of ciprofloxacin with erythromycin was antagonistic (24). Werk and Schneider found the combination of ciprofloxacin with metronidazole to be slightly more active for Clostridium perfringens and Clostridium difficile than ciprofloxacin or metronidazole alone were (43) .
DISCUSSION
In contrast, indifferent effects for the combinations of ciprofloxacin with metronidazole and clindamycin were detected by Watt and Brown (41) . Several studies have been published on SBA of quinolones in combination with other antibiotics, including combinations with vancomycin, amikacin, ceftazidime, piperacillin, and mezlocillin. The overall effect of these combinations was indifferent (29) .
In contrast to the in vitro data, in our investigation, enhanced activity against streptococci and staphylococci was found for the combinations of clindamycin with ciprofloxacin and ofloxacin (Table 2) , indicating a beneficial effect of these combinations in gram-positive infections. The high activity of quinolones against gram-negative bacteria was not affected. Surprisingly, there was no beneficial effect of the bactericidal activity against anaerobes by the combinations of both quinolones with metronidazole and clindamycin. The interpretation of this finding is difficult, since both metronidazole and clindamycin are substances with proven effects on anaerobic bacteria (9). However, there are some reports of resistance of clindamycin against the B. fragilis group (about 5%) (9) . There are limited data on the serum bactericidal test in anaerobic bacteria (8, 16, 34) , and only one study investigated clindamycin and metronidazole (40) . In this study by Van der Auwera et al., relatively low SBAs of clindamycin and metronidazole (less than 1:8, peak) against B. fragilis and B. thetaiotaomicron had also been found. However, the serum inhibitory activities, especially for clindamycin against B. fragilis, were distinctly higher in this study, whereas in our study, only slightly increased inhibitory activities were determined. The interpretation of both our results and the results of Van der Auwera et al. (40) in terms of their therapeutical value is difficult, since there is a lack of data correlating certain bactericidal titers in anaerobic bacteria with the clinical outcome. In aerobic bacteria, peak titers of21:8 and21:16 are correlated with favorable clinical outcomes in nonimmunocompromised and immunocompromised patients, respectively (38) . Thus, further clinical studies are needed to clarify this combination therapy in selected clinical situations.
Clinically relevant pharmacokinetic interactions between single and combined administration were not detected. However, there were significant differences between the volume of distribution for ciproflaxacin in the ciprofloxacin-metronidazole combination and of maximum concentration of drug in serum, the elimination half-life (tl12,3 and tl12,), and the volume of distribution for ofloxacin in the ofloxacin-clindamycin combination ( and in combination with metronidazole were remarkably long and showed a high variability compared with previous studies from our group and others (11, 27) . As outlined above, because of the high variability in this case, the median values probably give better information. However, there are still differences with our previous study on i.v. ofloxacin: by using a two-compartment model we found a terminal half-life of 256 min and a volume of distribution of 86.0 liters (compared with 258.5 liters in this study), whereas both the AUC (14.4 mg h/liter) and the clearances (total clearance, 234 ml/min) were comparable (27) . Farinotti and coworkers also noted a shorter terminal half-life (320 min) and a smaller volume of distribution (112 liters) for ofloxacin; however, the AUC (14.02 mg h/liter) and the clearances (total clearance, 241.06 ml/min) were also in the same range as in our study (11) .
For ciprofloxacin, the pharmacokinetic data were also different in some respects: the terminal half-life was 410.8 min, whereas in other studies half-lives between 180 and 265 min had been reported (4, 10, 19) . Compared with previous studies by our group and by others, a higher volume of distribution (4.6 to 5.8 liters/kg in this study, compared with 2.8 [4] and 2.3 [10] liters/kg) and a slightly higher clearance have also been detected. However, data for the AUC were in general agreement with data published by Drusano et al. (10) and our group (5, 19) .
The pharmacokinetics of clindamycin and metronidazole were in good agreement with the previous studies (21, 25, 39) . Study II. Only few studies published investigated the combination of enoxacin and fleroxacin with metronidazole, ornidazole, or clindamycin. Most in vitro investigations of interactions of various antibiotics with quinolones were performed with ciprofloxacin (29) . The studies available to date show no antagonism (29) . However, Heizmann et al., who investigated enoxacin in combination with metronidazole and clindamycin in mixed infections in an in vitro model, demonstrated a modification of in vitro susceptibility of the antibiotics in the presence of mixed aerobic and anaerobic pathogens. He concluded that in vitro susceptibility testing of mixed infections can be influenced by interactions between strains and antimicrobial agents (18) .
The results of SBA in our investigation are different in some respects from the results of study I. Against S. aureus, positive effects of the combinations of quinolones and clindamycin were not as evident as in study I: the combination of fleroxacin and clindamycin showed a slight increase (mean peak titer, 1:8.1 versus 1:4.3), whereas the combination of enoxacin and clindamycin showed no beneficial effect. Against E. coli and K. pneumoniae, the combination of enoxacin and metronidazole and, to a lesser extent, the combination of enoxacin and clindamycin resulted in decreases of serum bactericidal activity compared with enoxacin given alone (Table 4) . Although this result was somewhat unexpected, we would not interpret these results as an antagonism since a twofold error is inherent in a tube dilution method (36) and since these changes were not statistically significant. As shown with ciprofloxacin and ofloxacin, the SBA against P. aeruginosa was relatively low. Furthermore, the SBAs against anaerobic bacteria were relatively low, with peak titers ranging from 1:2.0 to 1:3.1. In addition to the issues discussed above (study I), in this study the oral regimen resulting in relatively low concentrations of both clindamycin and metronidazole in serum might partly explain the low SBA against both S. aureus and anaerobic bacteria (39) . Furthermore, our in vitro MIC and MBC data indicate that for metronidazole, the supplementation with serum increases the MBCs. Thus, especially at relatively low concentrations of the drug in serum, this effect could be more important than its bactericidal effect and possibly an additional factor in reducing the SBA of metronidazole. The pharmacokinetic results demonstrated no alteration of each drug in combined application. No significant differences were found between single and combined applications, except a significant difference between the elimination half-life of enoxacin when enoxacin was given with metronidazole and that with the single application. This difference does not seem to be of clinical relevance, because there were no significant differences concerning the most important parameters, such as the AUC and clearance. The data are in good agreement with the results of others (7, 21, 25, 31, 37, 42, 45) .
In summary, combinations of quinolones with clindamycin, metronidazole, and ornidazole indicate no clinically relevant alterations of the pharmacokinetics of each drug following oral (enoxacin and fleroxacin) or parenteral (ciprofloxacin and ofloxacin) administration. A beneficial effect of SBA against gram-positive pathogens could be demonstrated for the combinations with clindamycin; however, high i.v. doses of clindamycin seem to be necessary. It can be concluded that in clinical settings with severe mixed infections, a parenteral therapy consisting of modern quinolones together with clindamycin or imidazole derivatives appears to be active and offers no obvious interactions.
